Tuesday, June 16, 2009

Lung Cancer in American Women: Facts

From the National Lung Cancer Partnership:

  • Of the over 215,000 cases of lung cancer diagnosed in the U.S. each year, more than 100,300 (47%) are in women. Over 71,000 women die from lung cancer annually, accounting for 26 percent of cancer deaths among women. 1


  • One in 16 women will develop lung cancer in her lifetime.1


  • Lung cancer is the leading cancer killer of women in the U.S. 1


  • Lung cancer kills 30,000 more women than breast cancer annually in the U.S. 1


  • Lung cancer takes the lives of more women each year than breast, ovarian and uterine cancers combined. 1


  • The five year survival rate for lung cancer is only 16 percent compared to an 89 percent five year survival rate for breast cancer. 1, 2


  • 1 in 5 women with lung cancer has never smoked (in men with lung cancer, only 1 in 10 has never smoked).1 Women who have never smoked may be more at risk for lung cancer than men who have never smoked.3


  • Of the approximately 20,000-25,000 never-smokers diagnosed with lung cancer in the U.S. each year, more than 60 percent of them are women. 4


  • Of the approximately 3,400 people who die from lung cancer in the U.S. annually due to exposure from second-hand smoke, 2,200 (65%) of them are women. 5



  • Some evidence suggests that women may be more sensitive than men to the cancer-causing effects of chemicals in cigarettes.6-12



  • Approximately 9 percent of women diagnosed with lung cancer are younger then 50 years old, compared to 7 percent of men with lung cancer. 13



  • Women are more likely than men to get a sub-type of lung cancer called bronchioloalveolar carcinoma (BAC).13 The incidence of BAC appears to be rising worldwide. 15-17


  • Women typically fare better than men after treatment for lung cancer. 13, 18-22


  • Women with lung cancer are more likely than their male counterparts to have specific genetic mutations.9, 23-28 These mutations may be involved in lung cancer risk.


  • Research indicates that the female hormone estrogen may be involved in lung cancer risk in women. 29-32


  • Lung cancer research is significantly under-funded. In 2007, the National Cancer Institute spent approximately $1,415 per lung cancer death, compared to $13,991 per breast cancer death, $10,945 per prostate cancer death, and $4,952 per colorectal cancer death. 33-34


  • How Can I Reduce My Risk?

  • If you smoke, get the help you need to quit (state quitlines can be accessed at http://www.naquitline.org/ or by calling 1-800-QUIT-NOW).



  • If you live in an area with high levels of radon coming from the bedrock (see http://www.epa.gov/radon/ ), consider having your house tested for radon exposure. If radon levels are too high, a device can be installed to reduce them.



  • Eat a well-balanced diet and exercise. These activities help reduce the risk of all cancers.


  • If you smoke now or smoked in the past, or have a family history of lung cancer, consider speaking to your doctor about screening tests that may be available to you. Cancer is most treatable when it is detected early.


  • References Cited

    1. American Cancer Society. Cancer Facts and Figures 2008. Atlanta: American Cancer Society; 2008.
    2. American Cancer Society, Breast Cancer Facts & Figures 2005-2006. Atlanta: American Cancer Society, Inc.
    3. Wakelee, H.A., et al., Lung Cancer Incidence in Never Smokers. J Clin Oncol, 2007. 25(5): p. 472-8.
    4. MMWR Morb Mortal Wkly Rep. 2005. 54(25):625-628
    5. California Environmental Protection Agency. Proposed identification of environmental tobacco smoke as a toxic air contaminant-June 2005. California Environmental Protection Agency, California Air Resources Board, Office of Environmental Health Hazard Assessment; 2005.
    6. International Early Lung Cancer Action Program Investigators, Women’s susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA, 2006. 296(2): p. 180-84.
    7. Henschke, C.I. and O.S. Miettinen, Women's susceptibility to tobacco carcinogens. Lung Cancer, 2004. 43(1): p. 1-5.
    8. Nordlund, L.A., J.M. Carstensen, and G. Pershagen, Are male and female smokers at equal risk of smoking-related cancer: evidence from a Swedish prospective study. Scand J Public Health, 1999. 27(1): p. 56-62.
    9. Tang, D.L., et al., Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers. Carcinogenesis, 1998. 19(11): p. 1949-53.
    10. Zang, E.A. and E.L. Wynder, Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst, 1996. 88(3-4): p. 183-92.
    11. Risch, H.A., et al., Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol, 1993. 138(5): p. 281-93.
    12. Harris, R.E., et al., Race and sex differences in lung cancer risk associated with cigarette smoking. Int J Epidemiol, 1993. 22(4): p. 592-9.
    13. Fu, J.B., et al., Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest, 2005. 127(3): p. 768-77.
    14. Moore, R., et al., Sex differences in survival in non-small cell lung cancer patients 1974-1998. Acta Oncol, 2004. 43(1): p. 57-64.
    15. Jackman, D.M., L.R. Chirieac, and P.A. Janne, Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. Semin Respir Crit Care Med, 2005. 26(3): p. 342-52.
    16. Furak., J., et al., Bronchioloalveolar lung cancer: occurrence, surgical treatment and survival. Eur J Cardiothorac Surg, 2003. 23(5): p. 818-23.
    17. Barsky, S.H., et al., Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer, 1994. 73(4): p. 163-70.
    18. Kris, M.G., et al., Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama, 2003. 290(16): p. 2149-58.
    19. Fukuoka, M., et al., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003. 21(12): p. 2237-46.
    20. Alexiou, C., et al., Do women live longer following lung resection for carcinoma? Eur J Cardiothorac Surg, 2002. 21(2): p. 319-25.
    21. de Perrot, M., et al., Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg, 2000. 119(1): p. 21-6.
    22. Albain, K.S., J.J. Crowley, M. LeBlanc, and R.B. Livingston. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group database. J Clin Oncol. 1990. 8(9): p. 1563-74.
    23. Toyooka, S., T. Tsuda, and A.F. Gazdar, The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat, 2003. 21(3): p. 229-39.
    24. Mollerup, S., et al., Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res, 1999. 59(14): p. 3317-20.
    25. Nelson, H.H., et al., Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst, 1999. 91(23): p. 2032-8.
    26. Kure, E.H., et al., p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis, 1996. 17(10): p. 2201-5.
    27. Dresler, C.M., et al., Gender differences in genetic susceptibility for lung cancer. Lung Cancer, 2000. 30(3): p. 153-60.
    28. Ryberg, D., et al., Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res, 1994. 54(22): p. 5801-3.
    29. Stabile L.P. and J.M. Estrogen receptor pathways in lung cancer. Curr Oncol Rep. 2004 6(4): p. 259-67.
    30. Stabile, L.P., et al., Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res, 2002. 62(7): p. 2141-50.
    31. Fasco, M.J., G.J. Hurteau, and S.D. Spivack, Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol, 2002. 188(1-2): p. 125-40.
    32. Mooney, L.A., et al., Gender differences in autoantibodies to oxidative DNA base damage in cigarette smokers. Cancer Epidemiol Biomarkers Prev, 2001. 10(6): p. 641-8.
    33. American Cancer Society, Cancer Facts & Figures 2007. Atlanta: American Cancer Society; 2007.
    34. National Cancer Institute snapshots: http://planning.cancer.gov/disease/snapshots.shtml


    Please refer to our site for more detailed information.

No comments:

Post a Comment